所有患者在进入本临床实验前均已对依马替尼产生耐药，其中1 例获得过完全细胞遗传学缓解(complete cytogenetic responses, CCR)，4 例获得过部分细胞遗传学缓解(partial cytogenetic responses, PC...
基于4个网页-相关网页
... 得过完全细胞遗传学缓解(complete cytogenetic responses, CCR)，4例获得过部分细胞遗传学缓解(partial cytogenetic responses, PCR)，6例获得微小细胞遗传学缓解(minor cytogenetic responses, MCR)，5..
基于2个网页-相关网页
两组间血液学缓解和细胞遗传学缓解总有效率差异均有统计学意义。
Between the two groups, the total effective rates of the hematologic remission and cytogenetic response was significant difference.
结论TATS对初治及复发APL有一定的诱导分化作用，单药TATS治疗初治及复发apl患者可达到血液学和细胞遗传学缓解。
Conclusion TATS has a differentiation inducing effect on untreated and recurrent APL, with haematological CR and cytogenetic CR achieved.
结果：80 %患者达到血液学缓解，32 %患者产生细胞遗传学反应。
Results: 80 % of the patients reached the haematological alleviation, 32 % of the patients occurred cytogenetical reaction.
应用推荐